IP Library Granted Patent US 9,551,029
Granted Patent B2
US 9,551,029 · App. 14/927,908 · Granted Jan 24, 2017

Methods and kits using extended rhodamine dyes

Inventors: Joe Y. L. Lam (Castro Valley, CA); Scott C. Benson (Alameda, CA); Steven M. Menchen (Fremont, CA)
Assignee: APPLIED BIOSYSTEMS, LLC
C12Q1/6869C07D209/60C07D221/08C07D221/10C07D471/06C07D487/06C07D491/14C07H19/04C07H21/00C09B11/24C12Q1/68C12Q1/6816Y10S435/968Y10S435/975Y10S436/80Y10T436/143333
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,551,029
App. No.
14/927,908
Granted
Jan 24, 2017
Kind
B2
Abstract

Extended rhodamine compounds exhibiting favorable fluorescence characteristics having the structure are disclosed. In addition, novel intermediates for synthesis of these dyes are disclosed, such intermediates having the structure In addition, methods of making and using the dyes as fluorescent labels are disclosed.

Claims (64)

1. A kit for fragment analysis comprising one or more nucleoside or nucleotide, a chain-terminating nucleotide analog and a primer, wherein one or more of the nucleoside or nucleotide is a labelled nucleic acid compound comprising the structure:

wherein B is a nucleobase;

W1 and W2 taken separately are selected from —H, —OH, and —F; and W3 is selected from —OH, monophosphate, diphosphate, triphosphate and phosphate analog

L is a linkage; wherein if B comprises a purine base, the linkage is attached to the 8-position of the purine, if B comprises a 7-deazapurine base, the linkage is attached to the 7-position of the 7-deazapurine, and if B comprises a pyrimidine base, the linkage is attached to the 5-position of the pyrimidine; and

D is an extended rhodamine dye comprising the structure:

wherein

R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 9 , R 10 , R 11 , and R 13 when taken alone are selected from —H, alkyl, alkyl independently substituted with one or more Z 1 , heteroalkyl, heteroalkyl independently substituted with one or more Z 1 , aryl, aryl independently substituted with one or more Z 1 , heteroaryl, heteroaryl independently substituted with one or more Z 1 , arylalkyl, arylalkyl independently substituted with one or more Z 1 , heteroarylalkyl, heteroarylalkyl independently substituted with one or more Z 1 , halogen, —OS(O) 2 OR, —S(O) 2 OR, —S(O) 2 R, —S(O) 2 NR, —S(O)R, —OP(O)O 2 RR, —P(O)O 2 RR, —C(O)OR, —NR 2 , —NR 3 , —NC(O)R, —C(O)R, —C(O)NR 2 , —CN, and —OR, wherein R is independently selected from —H, alkyl, heteroalkyl, aryl, heteroaryl, arylalkyl, heteroarylalkyl and linking group; or

R 1 taken together with R 2 , Y 1 , or Y 2 ; or

R 4 taken together with R 3 , Y 3 , or Y 4 ; or

R 5 taken together with R 6 , Y 3 , or Y 4 ; or

R 6 taken together with R 7 , Y 3 , or Y 4 ; or

R 10 taken together with R 9 or R 11 ; or

R 11 taken together with Y 1 , or Y 2 ; or

R 13 taken together with Y 3 or Y 4 are selected from alkyleno, alkyleno independently substituted with one or more Z 1 , heteroalkyleno, heteroalkyleno independently substituted with one or more Z 1 , aryleno, aryleno independently substituted with one or more Z 1 , heteroaryleno, and heteroaryleno independently substituted with one or more Z 1 ;

R 5 is selected from —H, alkyl, alkyl independently substituted with one or more Z 1 , heteroalkyl, heteroalkyl independently substituted with one or more Z 1 , aryl, aryl independently substituted with one or more Z 1 , heteroaryl, heteroaryl independently substituted with one or more Z 1 , arylalkyl, arylalkyl independently substituted with one or more Z 1 , heteroarylalkyl, and heteroarylalkyl independently substituted with one or more Z 1 ;

Y 1 , Y 2 , Y 3 , Y 4 when taken alone are selected from —H, alkyl, alkyl independently substituted with one or more Z 1 , heteroalkyl, heteroalkyl independently substituted with one or more Z 1 , aryl, aryl independently substituted with one or more Z 1 , heteroaryl, heteroaryl independently substituted with one or more Z 1 , arylalkyl, arylalkyl independently substituted with one or more Z 1 , heteroarylalkyl, and heteroarylalkyl independently substituted with one or more Z 1 ; or

Y 1 taken together with R1, R11 or Y 2 ; or

Y 2 taken together with R1, R11 or Y 1 ; or

Y 3 taken together with R 4 , R 5 , R 6 , R 13 or Y 4 ; or

Y 4 taken together with R 4 , R 5 , R 6 , R 13 or Y 3 are selected from alkyleno, alkyleno independently substituted with one or more Z 1 , heteroalkyleno, heteroalkyleno independently substituted with one or more Z 1 , aryleno, aryleno independently substituted with one or more Z 1 , heteroaryleno, and heteroaryleno independently substituted with one or more Z 1 ;

Z 1 is selected from —R, halogen, —OS(O) 2 OR, —SO 2 OR, —SO 2 R, —SO 2 NR, —S(O)R, —OP(O)O 2 RR, —P(O)O 2 RR, —CO 2 R, —NR 2 , —NR 3 , —NC(O)R, —C(O)R, —C(O)NR 2 , —CN, —O and —OR, wherein R is independently selected from —H, alkyl, heteroalkyl, aryl, heteroaryl, arylalkyl, heteroarylalkyl and linking group; and

wherein the linkage is attached to R 8 of the extended rhodamine dye.

2. A kit for fragment analysis comprising one or more nucleotide triphosphates, a chain-terminating nucleotide analog and a primer, wherein one or more of the nucleotide triphosphates is a labelled nucleic acid compound comprising the structure:

wherein B is a nucleobase;

L is a linkage; wherein if B comprises a purine base, the linkage is attached to the 8-position of the purine, if B comprises a 7-deazapurine base, the linkage is attached to the 7-position of the 7-deazapurine, and if B comprises a pyrimidine base, the linkage is attached to the 5-position of the pyrimidine; and

D is an extended rhodamine dye comprising the structure:

wherein

R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 9 , R 10 , R 11 , and R 13 when taken alone are selected from —H, alkyl, alkyl independently substituted with one or more Z 1 , heteroalkyl, heteroalkyl independently substituted with one or more Z 1 , aryl, aryl independently substituted with one or more Z 1 , heteroaryl, heteroaryl independently substituted with one or more Z 1 , arylalkyl, arylalkyl independently substituted with one or more Z 1 , heteroarylalkyl, heteroarylalkyl independently substituted with one or more Z 1 , halogen, —OS(O) 2 OR, —S(O) 2 OR, —S(O) 2 R, —S(O) 2 NR, —S(O)R, —OP(O)O 2 RR, —P(O)O 2 RR, —C(O)OR, —NR 2 , —NR 3 , —NC(O)R, —C(O)R, —C(O)NR 2 , —CN, and —OR, wherein R is independently selected from —H, alkyl, heteroalkyl, aryl, heteroaryl, arylalkyl, heteroarylalkyl and linking group; or

R 1 taken together with R 2 , Y 1 , or Y 2 ; or

R 4 taken together with R 3 , Y 3 , or Y 4 ; or

R 5 taken together with R 6 , Y 3 , Or Y 4 ; or

R 6 taken together with R 7 , Y 3 , Or Y 4 ; or

R 10 taken together with R 9 or R 11 ; or

R 11 taken together with Y 1 , or Y 2 ; or

R 13 taken together with Y 3 or Y 4 are selected from alkyleno, alkyleno independently substituted with one or more Z 1 , heteroalkyleno, heteroalkyleno independently substituted with one or more Z 1 , aryleno, aryleno independently substituted with one or more Z 1 , heteroaryleno, and heteroaryleno independently substituted with one or more Z 1 ;

R 5 is selected from —H, alkyl, alkyl independently substituted with one or more Z 1 , heteroalkyl, heteroalkyl independently substituted with one or more Z 1 , aryl, aryl independently substituted with one or more Z 1 , heteroaryl, heteroaryl independently substituted with one or more Z 1 , arylalkyl, arylalkyl independently substituted with one or more Z 1 , heteroarylalkyl, and heteroarylalkyl independently substituted with one or more Z 1 ;

Y 1 , Y 2 , Y 3 , Y 4 when taken alone are selected from —H, alkyl, alkyl independently substituted with one or more Z 1 , heteroalkyl, heteroalkyl independently substituted with one or more Z 1 , aryl, aryl independently substituted with one or more Z 1 , heteroaryl, heteroaryl independently substituted with one or more Z 1 , arylalkyl, arylalkyl independently substituted with one or more Z 1 , heteroarylalkyl, and heteroarylalkyl independently substituted with one or more Z 1 ; or

Y 1 taken together with R1, R11 or Y 2 ; or

Y 2 taken together with R1, R11 or Y 1 ; or

Y 3 taken together with R 4 , R 5 , R 6 , R 13 or Y 4 ; or

Y 4 taken together with R 4 , R 5 , R 6 , R 13 or Y 3 are selected from alkyleno, alkyleno independently substituted with one or more Z 1 , heteroalkyleno, heteroalkyleno independently substituted with one or more Z 1 , aryleno, aryleno independently substituted with one or more Z 1 , heteroaryleno, and heteroaryleno independently substituted with one or more Z 1 ;

Z 1 is selected from —R, halogen, —OS(O) 2 OR, —SO 2 OR, —SO 2 R, —SO 2 NR, —S(O)R, —OP(O)O 2 RR, —P(O)O 2 RR, —CO 2 R, —NR 2 , —NR 3 , —NC(O)R, —C(O)R, —C(O)NR 2 , —CN, —O and —OR, wherein R is independently selected from —H, alkyl, heteroalkyl, aryl, heteroaryl, arylalkyl, heteroarylalkyl and linking group; and

wherein the linkage is attached to R 5 of the extended rhodamine dye.

3. A kit for fragment analysis comprising one or more nucleotide triphosphates, a chain-terminating nucleotide analog and a primer, wherein said chain-terminating nucleotide analog is a labelled nucleic acid compound comprising the structure:

wherein B is a nucleobase;

L is a linkage; wherein if B comprises a purine base, the linkage is attached to the 8-position of the purine, if B comprises a 7-deazapurine base, the linkage is attached to the 7-position of the 7-deazapurine, and if B comprises a pyrimidine base, the linkage is attached to the 5-position of the pyrimidine; and

D is an extended rhodamine dye comprising the structure:

wherein

R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 9 , R 10 , R 11 , and R 13 when taken alone are selected from —H, alkyl, alkyl independently substituted with one or more Z 1 , heteroalkyl, heteroalkyl independently substituted with one or more Z 1 , aryl, aryl independently substituted with one or more Z 1 , heteroaryl, heteroaryl independently substituted with one or more Z 1 , arylalkyl, arylalkyl independently substituted with one or more Z 1 , heteroarylalkyl, heteroarylalkyl independently substituted with one or more Z 1 , halogen, —OS(O) 2 OR, —S(O) 2 OR, —S(O) 2 R, —S(O) 2 NR, —S(O)R, —OP(O)O 2 RR, —P(O)O 2 RR, —C(O)OR, —NR 2 , —NR 3 , —NC(O)R, —C(O)R, —C(O)NR 2 , —CN, and —OR, wherein R is independently selected from —H, alkyl, heteroalkyl, aryl, heteroaryl, arylalkyl, heteroarylalkyl and linking group; or

R 1 taken together with R 2 , Y 1 , or Y 2 ; or

R 4 taken together with R 3 , Y 3 , or Y 4 ; or

R 5 taken together with R 6 , Y 3 , or Y 4 ; or

R 6 taken together with R 7 , Y 3 , Or Y 4 ; or

R 10 taken together with R 9 or R 11 ; or

R 11 taken together with Y 1 , or Y 2 ; or

R 13 taken together with Y 3 or Y 4 are selected from alkyleno, alkyleno independently substituted with one or more Z 1 , heteroalkyleno, heteroalkyleno independently substituted with one or more Z 1 , aryleno, aryleno independently substituted with one or more Z 1 , heteroaryleno, and heteroaryleno independently substituted with one or more Z 1 ;

R 5 is selected from —H, alkyl, alkyl independently substituted with one or more Z 1 , heteroalkyl, heteroalkyl independently substituted with one or more Z 1 , aryl, aryl independently substituted with one or more Z 1 , heteroaryl, heteroaryl independently substituted with one or more Z 1 , arylalkyl, arylalkyl independently substituted with one or more Z 1 , heteroarylalkyl, and heteroarylalkyl independently substituted with one or more Z 1 ;

Y 1 , Y 2 , Y 3 , Y 4 when taken alone are selected from —H, alkyl, alkyl independently substituted with one or more Z 1 , heteroalkyl, heteroalkyl independently substituted with one or more Z 1 , aryl, aryl independently substituted with one or more Z 1 , heteroaryl, heteroaryl independently substituted with one or more Z 1 , arylalkyl, arylalkyl independently substituted with one or more Z 1 , heteroarylalkyl, and heteroarylalkyl independently substituted with one or more Z 1 ; or

Y 1 taken together with R1, R11 or Y 2 ; or

Y 2 taken together with R1, R11 or Y 1 ; or

Y 3 taken together with R 4 , R 5 , R 6 , R 13 or Y 4 ; or

Y 4 taken together with R 4 , R 5 , R 6 , R 13 or Y 3 are selected from alkyleno, alkyleno independently substituted with one or more Z 1 , heteroalkyleno, heteroalkyleno independently substituted with one or more Z 1 , aryleno, aryleno independently substituted with one or more Z 1 , heteroaryleno, and heteroaryleno independently substituted with one or more Z 1 ;

Z 1 is selected from —R, halogen, —OS(O) 2 OR, —SO 2 OR, —SO 2 R, —SO 2 NR, —S(O)R, —OP(O)O 2 RR, —P(O)O 2 RR, —CO 2 R, —NR 2 , —NR 3 , —NC(O)R, —C(O)R, —C(O)NR 2 , —CN, —O and —OR, wherein R is independently selected from —H, alkyl, heteroalkyl, aryl, heteroaryl, arylalkyl, heteroarylalkyl and linking group; and

wherein the linkage is attached to R 8 of the extended rhodamine dye.

Assignments (4)
CHANGE OF NAME Recorded Sep 16, 2016
From: THE PERKIN-ELMER CORPORATION
To: APPLERA CORPORATION
Reel/Frame 040059/0755 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 16, 2016
From: LAM, JOE Y.L.; BENSON, SCOTT C.; MENCHEN, STEVEN M.
To: THE PERKIN-ELMER CORPORATION
Reel/Frame 039763/0182 →
MERGER Recorded Sep 16, 2016
From: APPLERA CORPORATION
To: APPLIED BIOSYSTEMS INC.
Reel/Frame 039763/0527 →
MERGER Recorded Sep 16, 2016
From: APPLIED BIOSYSTEMS INC.; ATOM ACQUISITION CORPORATION
To: APPLIED BIOSYSTEMS, LLC
Reel/Frame 039763/0972 →
Continuity (7)
Continuation 14098519 · Dec 5, 2013
Continuation 13365554 · Feb 3, 2012
Continuation 12846773 · Jul 29, 2010
Division 10925411 · Aug 24, 2004
Division 09780600 · Feb 9, 2001
Division 09325243 · Jun 3, 1999
Related Publication 20160122813A1 · May 5, 2016